GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corline Biomedical AB (OSTO:CLBIO) » Definitions » Debt-to-Asset

Corline Biomedical AB (OSTO:CLBIO) Debt-to-Asset : 0.00 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Corline Biomedical AB Debt-to-Asset?

Corline Biomedical AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Corline Biomedical AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Corline Biomedical AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was kr101.19 Mil. Corline Biomedical AB's debt to asset for the quarter that ended in Mar. 2024 was 0.00.


Corline Biomedical AB Debt-to-Asset Historical Data

The historical data trend for Corline Biomedical AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corline Biomedical AB Debt-to-Asset Chart

Corline Biomedical AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Corline Biomedical AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Corline Biomedical AB's Debt-to-Asset

For the Biotechnology subindustry, Corline Biomedical AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corline Biomedical AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corline Biomedical AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Corline Biomedical AB's Debt-to-Asset falls into.



Corline Biomedical AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Corline Biomedical AB's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Corline Biomedical AB's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Corline Biomedical AB  (OSTO:CLBIO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Corline Biomedical AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Corline Biomedical AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Corline Biomedical AB (OSTO:CLBIO) Business Description

Traded in Other Exchanges
N/A
Address
Lefflersgatan 5, Uppsala, SWE, 754 50
Corline Biomedical AB is involved in developing, manufacturing and marketing heparin-based solutions to improve kidney transplantation, cell therapies, and applications in the field of regenerative medicine.

Corline Biomedical AB (OSTO:CLBIO) Headlines

No Headlines